期刊文献+
共找到3,902篇文章
< 1 2 196 >
每页显示 20 50 100
Comparative Study on the Immunogenicity and Efficacy of Different Post-exposure Intramuscular Rabies Vaccination Regimens in China
1
作者 SONG Yun HE Ying +7 位作者 LU Xue Xin ZHANG Xiao Mei JIANG XIAO Lin SONG Qing HUANG Xue Yong MA Hong Xia YU Peng Cheng ZHU Wu Yang 《Biomedical and Environmental Sciences》 SCIE CAS CSCD 2024年第2期178-186,共9页
Objective This study aimed to compare the current Essen rabies post-exposure immunization schedule(0-3-7-14-28)in China and the simple 4-dose schedule(0-3-7-14)newly recommended by the World Health Organization in ter... Objective This study aimed to compare the current Essen rabies post-exposure immunization schedule(0-3-7-14-28)in China and the simple 4-dose schedule(0-3-7-14)newly recommended by the World Health Organization in terms of their safety,efficacy,and protection.Methods Mice were vaccinated according to different immunization schedules,and blood was collected for detection of rabies virus neutralizing antibodies(RVNAs)on days 14,21,28,35,and 120after the first immunization.Additionally,different groups of mice were injected with lethal doses of the CVS-11 virus on day 0,subjected to different rabies immunization schedules,and assessed for morbidity and death status.In a clinical trial,185 rabies-exposed individuals were selected for post-exposure vaccination according to the Essen schedule,and blood was collected for RVNAs detection on days 28and 42 after the first immunization.Results A statistically significant difference in RVNAs between mice in the Essen and 0-3-7-14 schedule groups was observed on the 35th day(P<0.05).The groups 0-3-7-14,0-3-7-21,and 0-3-7-28 showed no statistically significant difference(P>0.05)in RVNAs levels at any time point.The post-exposure immune protective test showed that the survival rate of mice in the control group was 20%,whereas that in the immunization groups was 40%.In the clinical trial,the RVNAs positive conversion rates on days 28(14 days after 4 doses)and 42(14 days after 5 doses)were both 100%,and no significant difference in RVNAs levels was observed(P>0.05).Conclusion The simple 4-dose schedule can produce sufficient RVNAs levels,with no significant effect of a delayed fourth vaccine dose(14–28 d)on the immunization potential. 展开更多
关键词 RABIES Post-exposure immunization Essen regimen RVNAs
下载PDF
Autologous hematopoietic stem cell transplantation conditioning regimens and chimeric antigen receptor T cell therapy in various diseases
2
作者 Shahzaib Maqbool Maryam Farhan Baloch +2 位作者 Muhammad Abdul Khaliq Khan Azeem Khalid Kiran Naimat 《World Journal of Transplantation》 2024年第1期32-41,共10页
Conditioning regimens employed in autologous stem cell transplantation have been proven useful in various hematological disorders and underlying malignancies;however,despite being efficacious in various instances,nega... Conditioning regimens employed in autologous stem cell transplantation have been proven useful in various hematological disorders and underlying malignancies;however,despite being efficacious in various instances,negative consequences have also been recorded.Multiple conditioning regimens were extracted from various literature searches from databases like PubMed,Google scholar,EMBASE,and Cochrane.Conditioning regimens for each disease were compared by using various end points such as overall survival(OS),progression free survival(PFS),and leukemia free survival(LFS).Variables were presented on graphs and analyzed to conclude a more efficacious conditioning regimen.In multiple myeloma,the most effective regimen was high dose melphalan(MEL)given at a dose of 200/mg/m2.The comparative results of acute myeloid leukemia were presented and the regimens that proved to be at an admirable position were busulfan(BU)+MEL regarding OS and BU+VP16 regarding LFS.In case of acute lymphoblastic leukemia(ALL),BU,fludarabine,and etoposide(BuFluVP)conferred good disease control not only with a paramount improvement in survival rate but also low risk of recurrence.However,for ALL,chimeric antigen receptor(CAR)T cell therapy was preferred in the context of better OS and LFS.With respect to Hodgkin’s lymphoma,mitoxantrone(MITO)/MEL overtook carmustine,VP16,cytarabine,and MEL in view of PFS and vice versa regarding OS.Non-Hodgkin’s lymphoma patients were administered MITO(60 mg/m2)and MEL(180 mg/m2)which showed promising results.Lastly,amyloidosis was considered,and the regimen that proved to be competent was MEL 200(200 mg/m2).This review article demonstrates a comparison between various conditioning regimens employed in different diseases. 展开更多
关键词 Conditioning regimens Multiple myeloma LYMPHOMA HODGKIN NON-HODGKIN Acute leukemia
下载PDF
疏肝解毒中药方配合R-CHOP方案治疗非霍奇金淋巴瘤的疗效及安全性研究
3
作者 贾景香 范宏宇 +2 位作者 孙立 赵婷 张晓刚 《海南医学》 CAS 2023年第23期3360-3365,共6页
目的基于白介素-17(IL-17)/白介素-23(IL-23)免疫炎症轴探究疏肝解毒中药方配合R-CHOP方案治疗非霍奇金淋巴瘤患者的疗效及安全性。方法选取2019年5月至2023年1月濮阳市中医院收治的50例非霍奇金淋巴瘤患者作为研究对象,按随机数表法分... 目的基于白介素-17(IL-17)/白介素-23(IL-23)免疫炎症轴探究疏肝解毒中药方配合R-CHOP方案治疗非霍奇金淋巴瘤患者的疗效及安全性。方法选取2019年5月至2023年1月濮阳市中医院收治的50例非霍奇金淋巴瘤患者作为研究对象,按随机数表法分为观察组和对照组各25例。对照组患者予以R-CHOP方案治疗,观察组患者在对照组治疗的基础上予以疏肝解毒中药方治疗,3周为一个疗程,共治疗4个疗程。治疗4个疗程后,比较两组患者的客观缓解率(ORR)、疾病控制率(DCR)、治疗安全性,治疗前和治疗2、4个疗程后的世界卫生组织生活质量(QOL)评分、T淋巴细胞亚群、血清κ轻链、λ轻链水平及L-17/IL-23免疫炎症轴的变化。结果治疗疗程结束后,观察组患者的ORR和DCR分别为80.00%、92.00%,明显高于对照组的52.00%、68.00%,差异均有统计学意义(P<0.05);治疗期间,观察组患者的恶心呕吐、白细胞减少、周围神经损伤发生率分别为24.00%、40.00%、28.00%,明显低于对照组的60.00%、80.00%、72.00%,差异均有统计学意义(P<0.05);治疗2、4个疗程后,观察组患者的QOL评分分别为(65.84±5.41)分、(82.44±8.24)分,明显高于对照组的(59.37±6.20)分、(75.64±7.22)分,差异均有统计学意义(P<0.05);治疗2、4个疗程后,观察组患者的CD3^(+)[(52.52±5.63)%、(57.25±7.12)%]、CD4^(+)[(31.02±4.78)%、(34.72±5.31)%]及CD4^(+)/CD8^(+)[1.21±0.08、1.36±0.12]明显高于对照组[(48.37±4.98)%、(45.24±4.07)%,(28.83±4.29)%、(26.09±3.72)%,1.16±0.09、1.10±0.08],差异均具有统计学意义(P<0.05);治疗2、4个疗程后,观察组患者的血清κ轻链[(1.92±0.45)g/L、(1.68±0.34)g/L]、λ轻链[(1.27±0.12)g/L、(0.97±0.10)g/L]明显低于对照组[(2.45±0.52)g/L、(1.89±0.40)g/L,(1.40±0.19)g/L、(1.15±0.14)g/L],差异均具有统计学意义(P<0.05);治疗2、4个疗程后,观察组患者的血清IL-17[(85.31±10.02)ng/L、(50.83±12.56)ng/L]、IL-23[(15.83±2.31)ng/L、(10.14±2.06)ng/L]明显低于对照组[(102.87±12.03)ng/L、(76.33±13.14)ng/L,(18.69±3.17)ng/L、(14.35±2.41)ng/L],差异均具有统计学意义(P<0.05)。结论疏肝解毒中药方配合R-CHOP方案治疗非霍奇金淋巴瘤能提高疗效,减少不良反应,改善免疫功能,降低血清轻链水平和IL-17/IL-23免疫炎症轴活性,促进病情缓解。 展开更多
关键词 非霍奇金淋巴瘤 疏肝解毒中药方 r-chop方案 IL-17/IL-23免疫炎症轴 疗效 安全性
下载PDF
Long-term outcomes of anti-VEGF treatment with 5+PRN regimen for macular edema due to central retinal vein occlusion 被引量:1
4
作者 Ya Ye Yu-Meng Deng +3 位作者 Zhen Huang Qiao-Wei Wu Yan-Nian Hui Yan-Ping Song 《International Journal of Ophthalmology(English edition)》 SCIE CAS 2023年第10期1642-1650,共9页
AIM:To assess the long-term outcomes of treating macular edema(ME)associated with central retinal vein occlusion(CRVO)with a regimen of“5+pro re nata(PRN)”.METHODS:This retrospective study included 27 eyes of 27 pat... AIM:To assess the long-term outcomes of treating macular edema(ME)associated with central retinal vein occlusion(CRVO)with a regimen of“5+pro re nata(PRN)”.METHODS:This retrospective study included 27 eyes of 27 patients with ME associated with non-ischemic CRVO(non-iCRVO group,n=15)and ischemic CRVO(iCRVO group,n=12).The eyes were treated with five consecutive intravitreal injections of conbercept or ranibizumab,followed by reinjections as needed or PRN.Retinal laser photocoagulation or intravitreal dexamethasone implants(DEX)were implemented in both groups when necessary.The best-corrected visual acuity(BCVA,logMAR)and central retinal thickness(CRT)were recorded at baseline,at 1,2,3,4,5,6,and 12mo,and at the final visit.The efficacy rates of BCVA and CRT before and after treatment were calculated.The number of injections at each visit and the incidence of adverse events were also recorded.RESULTS:The patients,aged 59.4±15.1y,were followed up for 24.7±8.8mo(range:15-42mo).After treatment,BCVA improved significantly from 1.04±0.56 logMAR at baseline to 0.59±0.36 logMAR(P=0.038)at the final visit in all patients.Both the non-iCRVO and the iCRVO groups achieved improved BCVA compared to the baseline at all visit points,but there was no statistical significance(P=0.197 and 0.33,respectively).The mean CRT was statistically reduced compared to baseline at all visit points in all the eyes and in both groups(all P<0.001).The apparent effective rate was 22.22% for BCVA and 37.04% for CRT after the first injection,48.15%for BCVA and 62.96% for CRT after 5 consecutive injections,and 74.08% for BCVA and 100% for CRT at the end of follow up.The average number of injections in all patients was 9.0±2.4 at 12mo and 14.9±8.1 finally with no statistical significance between both groups(P>0.05).Laser treatment was applied to all eyes in the iCRVO group,while only 5 patients in the noniCRVO group.Six patients in the non-iCRVO group and 3 patients in the iCRVO group had a drug switch.DEX was applied to 4 eyes in the non-iCRVO group and 5 eyes in the iCRVO group.CONCLUSION:The 5+PRN anti-vascular endothelial growth factor(VEGF)regimen is found to be safe and effective for both iCRVO and non-iCRVO,especially in the iCRVO group.The best regimen for such patients needs to be further investigated.Adjuvant laser therapy and DEX are necessary in some cases. 展开更多
关键词 central retinal vein occlusion macular edema anti-vascular endothelial growth factor regimen LASER dexamethasone implant
原文传递
组织多普勒成像技术对弥漫大B细胞淋巴瘤患者R-CHOP方案化疗后左心室舒张功能的定量评估
5
作者 王金娇 戴丽雅 +2 位作者 吕晴 毛玲玲 赵中伟 《全科医学临床与教育》 2023年第6期499-502,共4页
目的探讨组织多普勒成像技术(TDI)对弥漫大B细胞淋巴瘤(DLBCL)患者R-CHOP方案多次化疗后左心室舒张功能的定量评估。方法纳入60例经病理确诊为DLBCL、并接受R-CHOP方案多次化疗的患者,分别于化疗前(T0)、第1~6次化疗(记为T1~T6)后进行... 目的探讨组织多普勒成像技术(TDI)对弥漫大B细胞淋巴瘤(DLBCL)患者R-CHOP方案多次化疗后左心室舒张功能的定量评估。方法纳入60例经病理确诊为DLBCL、并接受R-CHOP方案多次化疗的患者,分别于化疗前(T0)、第1~6次化疗(记为T1~T6)后进行常规心脏超声检查,所有参数均测量3次取平均值,收集室间隔厚度(IVSd)、左心室收缩末期内径(LVESd)、左心室舒张末期后壁厚度(LVPWd)、左心室舒张末期内径(LVEDd)、左心室射血分数(LVEF)、二尖瓣舒张早期速度峰值(E)及舒张晚期速度峰值(A),E/A值;进入TDI模式,取得室间隔e’、侧壁e’、室间隔E/e’、侧壁E/e’及平均E/e’,比较7次左心室常规心脏超声参数与左心室TDI参数差异。结果60例患者T0~T6阶段IVSd、LVEDd、LVPWd、LVESd、LVEF参数比较,差异均无统计学意义(F分别=0.95、0.58、1.23、0.86、2.15,P均>0.05),但T0~T6时,患者E峰、A峰、E/A值呈下降趋势,差异均有统计学意义(F分别=9.65、2.75、4.02,P均<0.05)。T0~T6阶段的室间隔e'、侧壁e'及平均e'呈逐步下降趋势,室间隔E/e'、侧壁E/e'、平均E/e'呈逐步上升趋势,差异均有统计学意义(F分别=37.60、50.24、49.35、2.41、2.60、2.61,P均<0.05)。结论R-CHOP方案多次化疗后DLBCL患者左心室舒张功能下降,TDI技术可用于监测R-CHOP方案化疗后早期左心室舒张功能障碍。 展开更多
关键词 弥漫大B细胞淋巴瘤 r-chop 组织多普勒成像技术 左心室功能
下载PDF
Treatment outcomes and adverse drug reactions among patients with drug-resistant tuberculosis receiving all-oral,long-term regimens:First record viewing report from Pakistan
6
作者 Hira Aslam Asad Omar +6 位作者 Razia Fatima Usman Rasool Aashifa Yaqoob Waseem Ullah Aamir Khan Yusra Habib Khan Tauqeer Hussain Mallhi 《Asian Pacific Journal of Tropical Medicine》 SCIE CAS 2023年第2期58-64,I0003,共8页
Objective:To assess the effectiveness and adverse drug reactions of all-oral regimens for patients with multidrug-resistant tuberculosis.Methods:This retrospective study was conducted at 10 Programmatic Management of ... Objective:To assess the effectiveness and adverse drug reactions of all-oral regimens for patients with multidrug-resistant tuberculosis.Methods:This retrospective study was conducted at 10 Programmatic Management of Drug Resistant Tuberculosis sites in Punjab province of Pakistan.Patients receiving treatment for drug resistant tuberculosis from July 2019 to December 2020 with at least interim result i.e.6th month culture conversion or final outcomes(cured,complete,lost to follow-up,failure,death)available,were included in the study.Data was extracted from electronic data management system.For the reporting and management of adverse drug events,active tuberculosis drug safety monitoring and management was implemented across all sites.All the data was analyzed using SPSS version 22.Results:Out of 947 drug resistant tuberculosis patients included in this study,579(68%)of the patients had final outcomes available.Of these,384(67.9%)successfully completed their treatment.Out of 368(32%)patients who had their interim results available,all had their 6th month culture negative.Combining new medications was thought to result in serious adverse outcomes such as QT prolongation.However,this study did not record any severe adverse events among patients.Conclusions:All-oral regimens formulation guided by overall treatment effectiveness resulted in treatment outcomes comparable to those obtained with traditional injectable treatment. 展开更多
关键词 All-oral long-term regimens Long-term regimens Bedaquiline LINEZOLID CLOFAZIMINE Drug resistant tuberculosis Treatment outcomes aDSM
下载PDF
Early efficacy of individual regimens containing bedaquiline in patients with drug resistant tuberculosis
7
作者 Oki Nugraha Putra Yulistiani Yulistiani +1 位作者 Soedarsono Soedarsono Susi Subay 《Asian Pacific Journal of Tropical Medicine》 SCIE CAS 2023年第4期169-175,共7页
Objective:To evaluate early efficacy of sputum conversion within 6 months of individual regimens containing bedaquiline in patients with drug resistant tuberculosis.Methods:We conducted a retrospective study among pat... Objective:To evaluate early efficacy of sputum conversion within 6 months of individual regimens containing bedaquiline in patients with drug resistant tuberculosis.Methods:We conducted a retrospective study among patients with drug resistant tuberculosis who were receiving individual regimens containing bedaquiline.The primary outcome was sputum conversion of both smear and culture within 6 months of treatment.We used medical records of drug resistant tuberculosis patients from January 2020 to December 2021.The study was conducted at Dr.Soetomo Hospital,Indonesia from August to October 2022.Results:In this study,44 eligible drug resistant tuberculosis patients were initiated on regimens containing bedaquiline.There were 52.3%males and the median age was 45.5 years.The rates of previous treatment(70.5%)and lung cavity(36.4%)were high.The most common companion drugs included clofazimine,cycloserine,levofloxacin,and linezolid.Sputum smear and culture conversion was seen in 79.4%and 82.1%at the 2nd month,respectively.More than 97%patients had smear and culture conversion at the end of 6 months.Conclusions:Among drug resistant tuberculosis patients,individual regimens containing bedaquiline were associated with high rates of smear and culture conversion at the end of 6 months.Early efficacy of regimens containing bedaquiline can be used to predict cure rate at the end of treatment. 展开更多
关键词 Bedaquiline Individual regimen Drug resistant tuberculosis EFFICACY
下载PDF
Adjusting phosphate feeding regimen according to daily rhythm increases eggshell quality via enhancing medullary bone remodeling in laying hens
8
作者 Jiakun Yan Jiajie Wang +7 位作者 Jie Chen Hao Shi Xujie Liao Chong Pan Yanli Liu Xin Yang Zhouzheng Ren Xiaojun Yang 《Journal of Animal Science and Biotechnology》 SCIE CAS CSCD 2023年第3期1274-1286,共13页
Background Body phosphorus metabolism exhibits a circadian rhythm over the 24-h daily cycle.The egg laying behavior makes laying hens a very special model for investigating phosphorus circadian rhythms.There is lack o... Background Body phosphorus metabolism exhibits a circadian rhythm over the 24-h daily cycle.The egg laying behavior makes laying hens a very special model for investigating phosphorus circadian rhythms.There is lack of information about the impact of adjusting phosphate feeding regimen according to daily rhythm on the phosphorus homeostasis and bone remodeling of laying hens.Methods and results Two experiments were conducted.In Exp.1,Hy-Line Brown laying hens(n=45)were sampled according the oviposition cycle(at 0,6,12,and 18 h post-oviposition,and at the next oviposition,respectively;n=9 at each time point).Diurnal rhythms of body calcium/phosphorus ingestions and excretions,serum calcium/phosphorus levels,oviduct uterus calcium transporter expressions,and medullary bone(MB)remodeling were illustrated.In Exp.2,two diets with different phosphorus levels(0.32%and 0.14%non-phytate phosphorus(NPP),respectively)were alternately presented to the laying hens.Briefly,four phosphorus feeding regimens in total(each included 6 replicates of 5 hens):(1)fed 0.32%NPP at both 09:00 and 17:00;(2)fed 0.32%NPP at 09:00 and 0.14%NPP at 17:00;(3)fed 0.14%NPP at 09:00 and 0.32%NPP at 17:00;(4)fed 0.14%NPP at both 09:00 and 17:00.As a result,the regimen fed 0.14%NPP at 09:00 and 0.32%NPP at 17:00,which was designed to strengthen intrinsic phosphate circadian rhythms according to the findings in Exp.1,enhanced(P<0.05)MB remodeling(indicated by histological images,serum markers and bone mineralization gene expressions),elevated(P<0.05)oviduct uterus calcium transportation(indicated by transient receptor potential vanilloid 6 protein expression),and subsequently increased(P<0.05)eggshell thickness,eggshell strength,egg specific gravity and eggshell index in laying hens.Conclusions These results underscore the importance of manipulating the sequence of daily phosphorus ingestion,instead of simply controlling dietary phosphate concentrations,in modifying the bone remodeling process.Body phosphorus rhythms will need to be maintained during the daily eggshell calcification cycle. 展开更多
关键词 Body phosphorus rhythm Bone remodeling Eggshell formation Laying hen Phosphorus feeding regimen
下载PDF
Chemotherapy-free radiotherapy combined with immune checkpoint inhibitors:a new regimen for locally advanced non-small cell lung cancer?
9
作者 Lin Ma Liufu Deng +2 位作者 Jianfeng Peng Jinming Yu Xiangjiao Meng 《Cancer Biology & Medicine》 SCIE CAS CSCD 2023年第12期1035-1046,共12页
Maintenance immunotherapy after concurrent chemoradiotherapy remains the standard therapeutic approach in patients with unresectable locally advanced non-small cell lung cancer(LA-NSCLC).The efficacy of pembrolizumab ... Maintenance immunotherapy after concurrent chemoradiotherapy remains the standard therapeutic approach in patients with unresectable locally advanced non-small cell lung cancer(LA-NSCLC).The efficacy of pembrolizumab without chemotherapy in stage IV NSCLC has incited interest in similar approaches for LA-NSCLC.Several recent investigations involving the synergistic potential of immunotherapy combined with radiotherapy(i RT)have generated encouraging results.This review discusses the existing studies and prospective directions of chemotherapy-free i RT strategies in unresectable LA-NSCLC.Although the initial findings of chemotherapy-free i RT strategies have shown promising efficacy,we must consider the methodologic limitations of current studies and the myriad of challenges that accompany the implementation of chemotherapy-free i RT.These challenges include determining the optimal dose and fractionation,precise target volume delineation,and identification of additional suitable patient cohorts.Furthermore,the feasibility of chemotherapy-free i RT as a novel treatment modality for select patients with LA-NSCLC is contingent upon validation through randomized phase III trials. 展开更多
关键词 Locally advanced non-small cell lung cancer(LA-NSCLC) RADIOTHERAPY IMMUNOTHERAPY new regimen challenges
下载PDF
贝达喹啉联合背景方案治疗耐药肺结核的疗效
10
作者 冯治宇 邝浩斌 +3 位作者 汪敏 张宏 袁园 黄显林 《实用中西医结合临床》 2024年第1期6-9,共4页
目的:探讨贝达喹啉联合背景方案治疗耐药肺结核的疗效。方法:回顾性选择2022年1月至2023年1月广东省广州市胸科医院收治的159例耐药肺结核患者,按随机对照原则分组。对照组(80例)接受常规背景方案治疗,研究组(79例)在其基础上联合贝达... 目的:探讨贝达喹啉联合背景方案治疗耐药肺结核的疗效。方法:回顾性选择2022年1月至2023年1月广东省广州市胸科医院收治的159例耐药肺结核患者,按随机对照原则分组。对照组(80例)接受常规背景方案治疗,研究组(79例)在其基础上联合贝达喹啉治疗。于6个月后评估两组病灶吸收率、痰菌转阴率及空洞闭合率,对比两组治疗前后血清肝功能指标、心电图QTc变化,统计两组不良反应发生率。结果:研究组病灶吸收率、痰菌转阴率及空洞闭合率均较对照组高(P<0.05)。两组治疗后丙氨酸转氨酶(ALT)、天冬氨酸转氨酶(AST)水平升高(P<0.05);研究组治疗后ALT、AST水平与对照组相比,差异无统计学意义(P>0.05)。两组治疗后QTcF值升高,心率降低(P<0.05)。且研究组治疗后QTcF值比对照组高,心率比对照组低(P<0.05)。两组转氨酶升高、白细胞减少及胃肠道反应发生率对比,差异无统计学意义(P>0.05);研究组QT间期延长发生率显著高于对照组(P<0.05)。结论:贝达喹啉联合背景方案治疗耐药肺结核的疗效较佳,未引起肝功能指标异常,但QT间期延长发生率较高。 展开更多
关键词 耐药肺结核 贝达喹啉 背景方案 疗效 肝功能
下载PDF
以药动学/药效学模型为基础的多种比阿培南 给药方案对于重症感染性疾病的抗菌效果
11
作者 宋媛媛 江华东 孙莹莹 《中国当代医药》 CAS 2024年第2期14-18,共5页
目的以药动学/药效学(PK/PD)模型为基础,采用蒙特卡洛模拟,针对重症感染患者的个体差异,设计比阿培南个性化用药方案以改善临床效果。方法收集重症患者比阿培南药动学参数,以常见致病菌大肠埃希菌、肺炎克雷伯菌、铜绿假单胞菌、鲍曼不... 目的以药动学/药效学(PK/PD)模型为基础,采用蒙特卡洛模拟,针对重症感染患者的个体差异,设计比阿培南个性化用药方案以改善临床效果。方法收集重症患者比阿培南药动学参数,以常见致病菌大肠埃希菌、肺炎克雷伯菌、铜绿假单胞菌、鲍曼不动杆菌、金黄色葡萄球菌为目标菌株,引用中国细菌耐药监测研究报告中比阿培南对常见细菌最低抑菌浓度(MIC)值分布,通过调整给药剂量、给药间隔、滴注时间等方法制订不同给药方案,应用蒙特卡洛模拟计算各目标菌株不同给药方案的药效学获得概率(PTA)和累积反应分数(CFR),评估各给药方案治疗重症感染的抗菌效果。结果当MIC<0.125 mg/L时,比阿培南对5种目标菌株所有给药方案PTA值均>90%;当MIC≥4 mg/L时,所有给药方案PTA值均<90%;比阿培南对大肠埃希杆菌所有治疗方案CFR值均>90%,对鲍曼不动杆菌CFR值均<30%。结论比阿培南对大肠埃希菌的治疗可采用传统给药方案;对肺炎克雷伯菌的治疗可选择600 mg q6 h延时滴注3 h为最佳治疗方案,或根据MIC值优化给药方案;对于鲍曼不动杆菌、铜绿假单胞菌及金黄色葡萄球菌,应考虑换用或联用其他抗菌药物以达到疗效。 展开更多
关键词 比阿培南 蒙特卡洛模拟 药动学 药效学 重症患者 给药方案
下载PDF
国产两性霉素B脂质体不同加量方案在艾滋病合并马尔尼菲篮状菌感染患者中的安全性
12
作者 陈婷婷 张华堂 林志强 《国外医药(抗生素分册)》 CAS 2024年第1期56-60,共5页
目的探索国产两性霉素B脂质体临床应用中不同加量方案的安全性、常见不良反应及其影响因素。方法收集2017年1月—2022年12月我院收治的使用国产两性霉素B脂质体的艾滋病合并马尔尼菲篮状菌感染的病例,收集患者的基本资料、对比两性霉素... 目的探索国产两性霉素B脂质体临床应用中不同加量方案的安全性、常见不良反应及其影响因素。方法收集2017年1月—2022年12月我院收治的使用国产两性霉素B脂质体的艾滋病合并马尔尼菲篮状菌感染的病例,收集患者的基本资料、对比两性霉素B脂质体不同加量方案对血常规、肝肾功能及低钾血症的影响,统计发生的药品不良反应并使用多重线性回归法对用药后钾离子浓度的影响因素进行分析。结果共纳入50例患者,快速加量法(n=23,≤4d)与慢速加量法(n=27,>4d)对血常规、肝肾功能及钾离子浓度的影响均差异无统计学意义(P>0.05)。低钾血症(76.0%)是两性霉素B脂质体最常见不良反应,多重线性回归分析显示用药前钾离子浓度(P=0.008)是用药后钾离子浓度的重要影响因素。结论国产两性霉素B脂质体可安全使用快速加量法以尽快达到治疗剂量,该药临床应用中最常见不良反应为低钾血症,用药前钾离子浓度是用药后钾离子浓度的重要影响因素。 展开更多
关键词 两性霉素B脂质体 加量 艾滋病 马尔尼菲篮状菌 药品不良反应
下载PDF
超前镇痛方案对跟骨关节内骨折患者OPG/RANKL信号通路因子表达的影响
13
作者 王剑 欧阳彬 李强 《临床和实验医学杂志》 2024年第4期438-441,共4页
目的 探讨跟骨关节内骨折患者采用超前镇痛方案对骨保护素(OPG)/核因子-κB受体活化因子配体(RANKL)信号通路因子表达的影响。方法 回顾性选取2017年2月至2022年2月大庆油田总医院收治的跟骨关节内骨折患者100例,依据镇痛方案不同分为... 目的 探讨跟骨关节内骨折患者采用超前镇痛方案对骨保护素(OPG)/核因子-κB受体活化因子配体(RANKL)信号通路因子表达的影响。方法 回顾性选取2017年2月至2022年2月大庆油田总医院收治的跟骨关节内骨折患者100例,依据镇痛方案不同分为对照组和观察组,每组各50例。对照组患者接受常规性静脉自控镇痛方案,观察组患者接受地佐辛超前镇痛联合常规性静脉自控镇痛方案。统计分析两组围手术期指标(术中出血量、手术时间、术后引流量、术后引流时间、住院时间),麻醉前、手术前、手术后即刻的血流动力学(平均动脉压、心率),手术前、手术后1 d的应激反应[C反应蛋白(CRP)、肿瘤坏死因子-α(TNF-α)、白细胞介素-6(IL-6)、前列腺素E2(PGE2)],手术后即刻,手术后6 h、12 h、1 d的镇静[Ramsay镇静评分(RSS)、视觉模拟评分法(VAS)评分]和镇痛效果,以及手术后1 d、手术后1周的血清OPG、RANKL含量和术后并发症发生情况。结果 两组患者的术中出血量、手术时间比较,差异均无统计学意义(P>0.05);观察组患者的术后引流量为(59.86±2.54) mL,少于对照组[(110.97±9.41) mL],术后引流时间、住院时间分别为(123.23±9.82) h、(5.61±0.45) d,均短于对照组[(178.22±9.32) h、(8.01±0.31) d],差异均有统计学意义(P<0.05)。麻醉前、手术前、手术后即刻,两组患者的平均动脉压、心率比较差异均无统计学意义(P>0.05)。手术后1 d,两组患者的血清CRP、TNF-α、IL-6、PGE2水平均明显高于手术前,观察组患者的血清CRP、TNF-α、IL-6、PGE2水平分别为(5.11±1.47) mg/L、(43.15±7.51)μg/L、(32.52±5.31) ng/L、(138.11±12.68) pg/mL,均明显低于对照组[(21.42±3.44) mg/L、(87.60±13.56)μg/L、(75.77±21.35) ng/L、(144.60±15.20) pg/mL],差异均有统计学意义(P<0.05)。与手术后即刻比较,两组患者手术后6、12、24 h的RSS评分、VAS评分均逐渐降低,差异均有统计学意义(P<0.05);手术后6、12、24 h,两组患者的RSS评分、VAS评分比较差异均无统计学意义(P>0.05)。手术后1周,两组患者的血清OPG、RANKL含量均高于手术后1 d,且观察组患者的血清OPG、RANKL含量分别为(188.86±21.47)、(108.37±10.43) pg/mL,均高于对照组[(177.75±19.23)、(98.76±8.26) pg/mL],差异均有统计学意义(P<0.05)。观察组患者的术后并发症发生率为8.00%,明显低于对照组(32.00%),差异有统计学意义(P<0.05)。结论 超前镇痛方案能够促进跟骨关节内骨折患者OPG/RANKL信号通路因子表达及患者术后康复,提高镇痛效果,减少术后并发症的发生。 展开更多
关键词 跟骨 骨折 手术后并发症 超前镇痛方案 OPG/RANKL信号通路因子
下载PDF
世界卫生组织对BPaLM方案治疗耐多药结核病指南的解读
14
作者 段鸿飞 《中国医学前沿杂志(电子版)》 CSCD 北大核心 2024年第3期1-4,I0003,共5页
耐多药结核病仍是人类健康的重大危险因素,近期世界卫生组织推荐贝达喹啉(bedaquiline,Bdq)、普托马尼(pretomanid,Pa)、利奈唑胺(linezolid,Lzd)和莫西沙星(moxifloxacin,Mfx)的6个月方案(BPaLM)治疗耐多药结核病。新指南中短程方案适... 耐多药结核病仍是人类健康的重大危险因素,近期世界卫生组织推荐贝达喹啉(bedaquiline,Bdq)、普托马尼(pretomanid,Pa)、利奈唑胺(linezolid,Lzd)和莫西沙星(moxifloxacin,Mfx)的6个月方案(BPaLM)治疗耐多药结核病。新指南中短程方案适用人群扩大到耐多药结核病患者,而且适用于病变广泛的肺结核和大多数肺外结核,无疑是耐多药结核病治疗的重要事件。本文就BPaLM方案的研究历程、适用人群和注意事项作一简要介绍。 展开更多
关键词 耐多药/利福平耐药结核病 短程治疗 世界卫生组织
下载PDF
重组人血管内皮抑制素注射液联合GP化疗方案治疗晚期NSCLC的可行性
15
作者 宋永波 赵璐 +1 位作者 张艳苓 任武 《临床合理用药杂志》 2024年第12期13-16,共4页
目的观察重组人血管内皮抑制素注射液联合GP化疗方案治疗晚期非小细胞肺癌(NSCLC)的可行性。方法回顾性选取2020年5月—2022年12月皖北煤电集团总医院肿瘤内科收治的晚期NSCLC患者80例,将采用GP化疗方案治疗者纳入GP化疗组(n=40),重组... 目的观察重组人血管内皮抑制素注射液联合GP化疗方案治疗晚期非小细胞肺癌(NSCLC)的可行性。方法回顾性选取2020年5月—2022年12月皖北煤电集团总医院肿瘤内科收治的晚期NSCLC患者80例,将采用GP化疗方案治疗者纳入GP化疗组(n=40),重组人血管内皮抑制素注射液联合GP化疗方案治疗者纳入联合用药组(n=40),2组均以3周为1个治疗周期,共治疗2个周期。比较2组患者近期疗效,用药前后实验室指标、生活质量评分,不良反应及1年存活率。结果联合用药组客观缓解率为85.00%,高于GP化疗组的52.50%(χ^(2)=9.833,P=0.002)。用药2个周期后,2组血清癌胚抗原、糖类抗原125水平低于用药前,凝血酶时间、活化部分凝血活酶时间短于用药前,凝血酶原时间长于用药前,血浆纤维蛋白原、D-二聚体水平高于用药前,且联合用药组各指标优于对照组(P<0.05或P<0.01);2组生理功能、躯体功能、精神状态、社会关系评分高于用药前,且联合用药组高于GP化疗组(P<0.01)。联合用药组与GP化疗组不良反应总发生率分别为22.50%、15.00%,组间比较差异无统计学意义(χ^(2)=0.738,P=0.390)。联合用药组1年存活率为65.00%,高于GP化疗组的42.50%(χ^(2)=4.073,P=0.044)。结论晚期NSCLC治疗中采用重组人血管内皮抑制素注射液联合化疗药物的可行性较高,可有效降低肿瘤标志物水平,延缓病情进展,提高患者生活质量及1年存活率,且具有一定安全性。 展开更多
关键词 非小细胞肺癌 晚期 GP化疗方案 重组人血管内皮抑制素注射液 肿瘤标志物 凝血功能 不良反应
原文传递
R-CHOP方案与CHOP方案治疗初治弥漫性大B细胞淋巴瘤的临床研究 被引量:21
16
作者 徐卫 李建勇 +5 位作者 张智弘 仇红霞 钱思轩 吴汉新 陆化 盛瑞兰 《中国实验血液学杂志》 CAS CSCD 2008年第4期933-937,共5页
为比较利妥昔单克隆抗体联合标准CHOP方案与标准CHOP方案治疗初治CD20阳性的弥漫慢大B细胞淋巴瘤(DLBCL)患者的疗效和安全性,采用同期(2003年7月至2006年12月)非随机对照的前瞻性研究方法,将69例在我院住院的初治DLBCL患者分为R-CHOP组... 为比较利妥昔单克隆抗体联合标准CHOP方案与标准CHOP方案治疗初治CD20阳性的弥漫慢大B细胞淋巴瘤(DLBCL)患者的疗效和安全性,采用同期(2003年7月至2006年12月)非随机对照的前瞻性研究方法,将69例在我院住院的初治DLBCL患者分为R-CHOP组和CHOP组,其中CHOP组36例,R-CHOP组33例,比较两组的完全缓解率、生存期及不良反应情况。结果显示:R-CHOP组23例(69.7%)获完全缓解(CR),部分缓解(PR)6例(18.2%),总有效率为88.5%,高于CHOP组;CHOP组17例(47.2%)获CR,11例(30.6%)获PR,总有效率77.8%(p=0.049)。尤其在男性、Ann ArborⅢ-Ⅳ和IPI3-5分的患者中,R-CHOP方案的CR率明显高于CHOP方案,且差异具有统计学意义(p=0.017、p=0.005和p=0.000)。R-CHOP组预计的平均生存时间(OS)为45.7个月,长于CHOP组的35.2个月,但经Log-Rank检验,差异无统计学意义(p=0.145);R-CHOP组预计的平均无疾病进展生存时间(PFS)为38.5个月,长于CHOP组的24.6个月,经Log-Rank检验,差异有统计学意义(p=0.017)。R-CHOP组的不良反应主要为发热等输注相关的不良反应,而骨髓抑制情况与CHOP组类似。结论:利妥昔单克隆抗体联合CHOP方案治疗CD20阳性的DLBCL与单纯CHOP方案相比,能显著提高疗效,同时并不增加化疗的毒副反应。 展开更多
关键词 淋巴瘤 利妥昔单克隆抗体 CHOP方案 R—CHOP方案
下载PDF
贝伐珠单抗联合TP化疗方案治疗晚期NSCLC的疗效
17
作者 刘江涛 李亭亭 赵宁 《临床合理用药杂志》 2024年第12期1-4,8,共5页
目的观察贝伐珠单抗联合TP化疗方案治疗晚期非小细胞肺癌(NSCLC)的临床疗效。方法回顾性选取2020年1月-2022年12月滨州市中心医院收治的晚期NSCLC患者60例,依据用药方法不同分为TP化疗组(n=30)、联合化疗组(n=30)。TP化疗组患者采用TP... 目的观察贝伐珠单抗联合TP化疗方案治疗晚期非小细胞肺癌(NSCLC)的临床疗效。方法回顾性选取2020年1月-2022年12月滨州市中心医院收治的晚期NSCLC患者60例,依据用药方法不同分为TP化疗组(n=30)、联合化疗组(n=30)。TP化疗组患者采用TP化疗方案治疗,联合化疗组患者在TP化疗组基础上给予贝伐珠单抗注射液治疗,2组均以3周为1个周期,共治疗4个周期。比较2组近期疗效,化疗前后肿瘤标志物(癌胚抗原、糖类抗原125、细胞角蛋白19片段抗原21-1、神经元特异性烯醇化酶)、血管生成促进因子[碱性成纤维细胞生长因子(bFGF)、血管内皮生长因子(VEGF)]、免疫指标(CD3^(+)、CD4^(+)、CD8^(+)、CD4^(+)/CD8^(+))、视觉模拟评分法(VAS)评分、生活质量评定量表(QOL)评分,不良反应,中位生存期,无进展生存期。结果联合化疗组疾病控制率为96.67%,高于TP化疗组的73.33%(χ^(2)=4.706,P=0.030)。化疗4个周期后,2组癌胚抗原、糖类抗原125、细胞角蛋白19片段抗原21-1、神经元特异性烯醇化酶、bFGF、VEGF水平低于化疗前,且联合化疗组低于TP化疗组(P<0.05或P<0.01);2组CD3^(+)、CD4^(+)、CD4^(+)/CD8^(+)高于化疗前,CD8^(+)低于化疗前,且联合化疗组高/低于TP化疗组(P<0.01);2组VAS评分低于化疗前,QOL评分高于化疗前,且联合化疗组低/高于TP化疗组(P<0.01)。TP化疗组与联合化疗组不良反应发生率比较,差异无统计学意义(P>0.05)。联合化疗组中位生存期、无进展生存期长于TP化疗组(P<0.01)。结论贝伐珠单抗与TP化疗方案联合应用于晚期NSCLC的治疗,效果显著,能有效降低患者的肿瘤标志物水平,提高免疫功能,抑制肿瘤进展,并提升生活质量,可延长患者的生存期,且不会增加不良反应。 展开更多
关键词 非小细胞肺癌 晚期 贝伐珠单抗 TP化疗方案 肿瘤标志物 免疫指标 不良反应 生存期
原文传递
达格列净结合标准抗心衰及降糖方案治疗老年慢性心力衰竭合并T2DM及高尿酸血症的临床分析
18
作者 钟明江 黄红梅 李俐 《中外医疗》 2024年第1期36-40,共5页
目的探究对老年慢性心力衰竭合并2型糖尿病(Diabetes Mellitus Type 2,T2DM)及高尿酸血症患者采用达格列净和标准抗心衰及降糖方案结合治疗后效果。方法随机选取2021年6月—2022年6月广州市花都区人民医院收治的心力衰竭合并T2DM及高尿... 目的探究对老年慢性心力衰竭合并2型糖尿病(Diabetes Mellitus Type 2,T2DM)及高尿酸血症患者采用达格列净和标准抗心衰及降糖方案结合治疗后效果。方法随机选取2021年6月—2022年6月广州市花都区人民医院收治的心力衰竭合并T2DM及高尿酸血症患者120例为研究对象,采用随机数表法分成对照组(60例)、观察组(60例)。对照组采取标准抗心衰及降糖方案,观察组在对照组基础上采取达格列净,对比临床效果。结果观察组氨基末端脑钠肽前体(N Terminal Pro B Type Natriuretic Peptide,NT-proBNP)为(519.36±107.52)ng/L、血尿酸为(346.17±42.15)μmol/L低于对照组,差异有统计学意义(t=2.020、4.245,P<0.05)。观察组血脂改善更好,左室舒张末容积、左室收缩末容积、舒张早期二尖瓣血流速度/二尖瓣环运动速度(the Ratio of Early Diastolic Transmitral Flow Velocity to Mitral Annular Velocity,E/e’)低于对照组,左室射血分数高于对照组,差异有统计学意义(P<0.05)。观察组主要终点事件、次要终点事件、痛风发作率低于对照组,差异有统计学意义(P<0.05)。两组药物不良反应率对比,差异无统计学意义(P>0.05)。结论针对老年慢性心力衰竭合并T2DM及高尿酸血症患者,采用达格列净联合标准抗心衰及降糖方案,能改善血脂、心功能等指标水平,预后效果以及安全性较高。 展开更多
关键词 达格列净 标准抗心衰及降糖方案 老年慢性心力衰竭合并2型糖尿病及高尿酸血症 临床效果
下载PDF
苯达莫司汀联合利妥昔单抗与R-CHOP方案一线治疗惰性非霍奇金淋巴瘤或套细胞淋巴瘤疗效及安全性比较 被引量:6
19
作者 张馨予 徐卫 刘思初 《循证医学》 CSCD 2016年第2期73-75,共3页
利妥昔单抗联合包含环磷酰胺、阿霉素、长春新碱和泼尼松的R—CHOP方案是目前治疗进展期惰性非霍奇金淋巴瘤(indolentnon.Hodgkin’slymphoma,iNHL)和套细胞淋巴瘤(mantlecelllymphoma,MCL)常用的一线方案。
关键词 惰性非霍奇金淋巴瘤 套细胞淋巴瘤 BR方案 r-chop方案 无进展生存期
下载PDF
上一页 1 2 196 下一页 到第
使用帮助 返回顶部